The MYEOV (myeloma overexpressed) gene is located at 11q13.3 and IGH (immunoglobulin heavy locus) at 14q32.33. Approximately 50-60% of multiple myeloma (MM) cases are associated with translocations involving IGH and one of several partners including CCND1, NSD2 (WHSC1) and FGFR3, CCND3, MAF or MAFB1 . The t(11;14)(q13;q32) translocation is the most common translocation in MM, where it is seen in approximately 15% of cases2,3 . Unlike mantle cell lymphoma (MCL), where the breakpoints are clustered in a 1kb region that is 120kb centromeric to the CCND1 gene4 , the breakpoints in MM cases are dispersed within a 360kb region between CCND1 and MYEOV at 11q135 . MYEOV is a putative oncogene, located 360kb centromeric to CCND1, which is thought to be activated in the translocation by becoming closely associated with IGH enhancers. In contrast to IGH rearrangements in other neoplasms, those found in MM have IGH breakpoints predominantly in the C/J region, which, in the case of MYEOV, brings the MYEOV gene under the control of the 3′ Eα1 enhancer5 . In CCND1 translocations by contrast, the Eμ enhancer controls CCND1 expression. MYEOV overexpression is a possible prognostic factor in MM6 . The t(11;14)(q13;q32) associated with a favourable outcome in most series and therefore is regarded as neutral with regard to prognosis3 .
Probe Specification MYEOV, 11q13.3, Red IGH, 14q32.33, Green
Avaliações
Não há avaliações ainda.